These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 1850874)

  • 1. The initial release of t-PA induced by dDAVP is more important with low molecular weight heparin than with unfractionated heparin.
    Schved JF; Gris JC; Sarlat C
    Thromb Haemost; 1991 Jan; 65(1):109. PubMed ID: 1850874
    [No Abstract]   [Full Text] [Related]  

  • 2. Additive effect of dDAVP and standard heparin in increasing plasma t-PA.
    Agnelli G; Levi M; Cosmi B; ten Cate JW; Nenci GG
    Thromb Haemost; 1989 Jun; 61(3):507-10. PubMed ID: 2508260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different tissue plasminogen activator release in the arm and leg during venous occlusion is equalized after DDAVP infusion.
    Keber D; Stegnar M; Kluft C
    Thromb Haemost; 1990 Feb; 63(1):72-5. PubMed ID: 2111049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Problems in measuring parameters of the fibrinolytic system: circadian rhythm of tissue-type plasminogen activator and plasminogen activator inhibitor].
    Köhler M; Miyashita C
    Klin Wochenschr; 1988; 66 Suppl 12():62-7. PubMed ID: 3126347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological stimulation of t-PA release.
    Klöcking HP; Markwardt F
    Pharmazie; 1994 Apr; 49(4):227-30. PubMed ID: 7910971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Norepinephrine and DDAVP induced rise in tissue plasminogen activator.
    Grant PJ; Wiles PG; Davies JA; Prentice CR
    Thromb Haemost; 1988 Oct; 60(2):342. PubMed ID: 3146147
    [No Abstract]   [Full Text] [Related]  

  • 7. Renal and hepatic handling of endogenous tissue-type plasminogen activator (t-PA) and its inhibitor in man.
    Brommer EJ; Derkx FH; Schalekamp MA; Dooijewaard G; vd Klaauw MM
    Thromb Haemost; 1988 Jun; 59(3):404-11. PubMed ID: 3142078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DDAVP induces systemic release of urokinase-type plasminogen activator.
    Levi M; ten Cate JW; Dooijewaard G; Sturk A; Brommer EJ; Agnelli G
    Thromb Haemost; 1989 Sep; 62(2):686-9. PubMed ID: 2510348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Low molecular weight heparin CY 222 (Choay) potentiates the thrombolytic effect of 1-PA in rabbits with experimental thrombosis of the jugular vein].
    Juhan-Vague I; Stassen JM; Alessi MC; de Cock F; Serradimigni A; Collen D
    J Mal Vasc; 1987; 12 Suppl B():64-5. PubMed ID: 2834493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 1-Desamino-8-D-arginine vasopressin (DDAVP) in patients with congenital nephrogenic diabetes insipidus.
    Brink HS; Derkx FH; Boomsma F; Brommer EJ; Schalekamp MA
    Neth J Med; 1993 Aug; 43(1-2):5-12. PubMed ID: 8232694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Less pronounced enhancement of thrombin-dependent inactivation of plasminogen activator inhibitor type 1 by low molecular weight heparin compared with unfractionated heparin.
    Nakamura R; Umemura K; Hashimmoto H; Urano T
    Thromb Haemost; 2006 Apr; 95(4):637-42. PubMed ID: 16601834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heparin, DDAVP and the bleeding time.
    Schulman S; Johnsson H
    Thromb Haemost; 1991 Mar; 65(3):242-4. PubMed ID: 2048049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secretory response of the vessel wall to DDAVP and venous occlusion in von Willebrand's disease.
    Bykowska K; Letowska M; Sabliński J; Binder BR; Kopeć M; Lopaciuk S
    Acta Haematol Pol; 1994; 25(3):261-8. PubMed ID: 7992599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A dynamic test to investigate potential tissue plasminogen activator activity. Comparison of deamino-8-D-argininevasopressin with venous occlusion in normal subjects and patients.
    Sultan Y; Harris A; Strauch G; Venot A; De Lauture D
    J Lab Clin Med; 1988 Jun; 111(6):645-53. PubMed ID: 3131470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of uPA release in human peripheral blood lymphocytes by [deamino-Cysl,D-Arg8]-vasopressin (dDAVP).
    Yamaguchi Y; Yamada K; Suzuki T; Wu YP; Kita K; Takahashi S; Ichinose M; Suzuki N
    Am J Physiol Endocrinol Metab; 2004 Nov; 287(5):E970-6. PubMed ID: 15198931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potentiation by heparin fragments of thrombolysis induced with human tissue-type plasminogen activator or human single-chain urokinase-type plasminogen activator.
    Stassen JM; Juhan-Vague I; Alessi MC; De Cock F; Collen D
    Thromb Haemost; 1987 Oct; 58(3):947-50. PubMed ID: 2829381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Marked potentiation of the plasminogenolytic activity of pro-urokinase by unfractionated heparin and a low molecular-weight heparin.
    Dosne AM; Bendetowicz AV; Kher A; Samama M
    Thromb Res; 1988 Sep; 51(6):627-30. PubMed ID: 2847356
    [No Abstract]   [Full Text] [Related]  

  • 18. Heparin and fibrinolysis--comparison of subcutaneous administration of unfractionated and low molecular weight heparin.
    Eriksson E; Wollter IM; Christenson B; Stigendal L; Risberg B
    Thromb Haemost; 1988 Apr; 59(2):284-8. PubMed ID: 2838926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of heparin and other glycosaminoglycans on levels of tissue plasminogen activator and plasminogen activator inhibitor in cultured human umbilical vein endothelial cells.
    Marsh NA; Minter AJ; Chesterman CN
    Blood Coagul Fibrinolysis; 1990 Jun; 1(2):133-8. PubMed ID: 1966669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the fibrinolytic response to desmopressin acetate (DDAVP) infusion versus venous occlusion in patients with coronary artery disease.
    Duprez D; Baele G; De Buyzere M; Vandenbroecke P; Clement DL
    Eur Heart J; 1991 Jul; 12(7):800-2. PubMed ID: 1909628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.